

[Practice/Organization Logo]

FOR IMMEDIATE RELEASE

[Insert Practice/Organization Name] Now Offering YUVEZZI™, the
First and Only Dual-Agent Eye Drop for Presbyopia

Presbyopia is the gradual loss of close-up vision that typically begins around
age 45 and impacts nearly 128 million people in the U.S.^{1,2,3}

[City, State], [Month Day, Year] – The eye care professionals at [insert ECP practice] are pleased to now offer YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent (combination) eye drop approved for the treatment of presbyopia in adults, in our practice.

Presbyopia, the gradual loss of close-up vision that typically begins around age 45, is a natural, inevitable part of aging.¹ The condition affects the lens' ability to change shape and focus on close objects.⁴

YUVEZZI is a once daily prescription eye drop for presbyopia that was approved by the U.S. Food & Drug Administration (FDA) in January 2026. It combines two medicines, carbachol and brimonidine, that work together to improve close-up vision. In medical studies, YUVEZZI provided up to 8 continuous hours of improved close-up vision.⁵ As soon as 30 minutes after taking YUVEZZI, some people could clearly read at least 3 more lines on an eye chart in low light without losing distance vision.⁵

Please see Important Safety Information for YUVEZZI below.

[See quote options below. Please select and use the option you prefer, but do not alter the language outside of adding your name and practice name.]

[Option 1] "Over the years, I've seen how presbyopia can quietly chip away at independence as people age. Patients tell me they're frequently reaching for readers just to send a text, sign a form or check a receipt," said Dr. [Name], [OD/M.D.], [Title/Practice Name]. "People may feel 'too young' to need reading glasses, yet they're already changing habits at work and at home as near vision has become more of a challenge. [Practice Name] is now proud to offer YUVEZZI eye drops as a non-invasive option designed to help adults see up close more clearly with the simplicity of once-daily dosing. Adding an innovative treatment like this expands how we can personalize care and helps more of our patients stay present in the moments that matter to them."

[Option 2] "Presbyopia is one of the most common vision changes we see, but that doesn't make it any less disruptive to daily life," said Dr. [Name], [OD/M.D.], [Title/Practice Name]. "Many adults are surprised by how often difficulty seeing up close affects simple routines like reading a menu, replying to a text, looking at labels or reviewing paperwork. At [Practice Name], we're pleased to now offer YUVEZZI eye drops as a non-invasive, once daily-dosing option for adults with presbyopia. It gives us another way to support patients who want clearer near vision and flexibility in how they manage their eye care."

[Option 3] "Presbyopia can be frustrating because it often appears gradually, and patients don't always realize how much they've adapted until near tasks become consistently difficult," said Dr. [Name], [OD/M.D.], [Title/Practice Name]. "We hear from adults who are holding their phone farther away, relying more on readers or feeling inconvenienced during everyday activities at home and at work. That's why we're excited to now offer YUVEZZI at [Practice Name]. As a once-daily, non-invasive option, it allows us to broaden the conversation around presbyopia care and offer patients another approach to improving close-up vision."

YUVEZZI was studied in the world's largest and longest presbyopia safety study.⁵ The most common side effects were headache (16% of patients), eye irritation upon use (14% of patients), eye pain upon use (7% of patients) and impaired vision (6% of patients). Most side effects were generally mild, didn't last long, and went away on their own.⁵

If you are interested in exploring options for your blurry close-up vision, reach out to our team to learn more about YUVEZZI and if it may be right for you.

About YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%

YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a dual-agent eye drop approved by the U.S. Food & Drug Administration (FDA) for the treatment of presbyopia, a condition characterized by the gradual loss of near vision acuity that typically begins after the age of 45.^{5,2}



The proposed mechanism of action of this fixed-dose combination of carbachol and brimonidine in presbyopia is pupillary constriction and the creation of a pinhole effect that improves near visual acuity and depth of focus.⁵ Carbachol is a cholinergic agent which produces constriction of the iris sphincter and ciliary body. Brimonidine tartrate, an alpha-adrenergic agonist, blocks contraction of the iris dilator muscle and relaxes tonic contraction of the ciliary muscle, enhancing selectivity for the pupil and increasing bioavailability of carbachol in the aqueous humor.⁵

For more information about YUVEZZI™ and full **Prescribing Information**, please visit www.YUVEZZI.com.

YUVEZZI™ Indication and Important Safety Information

USE

YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75% / 0.1% is a prescription eye drop for adults with blurry close-up vision due to age.

IMPORTANT SAFETY INFORMATION

Do not use YUVEZZI if you are allergic to any of its ingredients or if you currently have inflammation of the iris (iritis).

Before taking YUVEZZI, tell your doctor if you have depression, low blood pressure, or circulation problems.

YUVEZZI may cause temporary blurry, dim, or dark vision. If you experience this, avoid driving, using machinery, and participating in hazardous activities. Use caution when night driving and in other activities in low light.

Call your doctor right away if you suddenly have flashes of light, floaters, or vision loss.

Do not let the tip of the vial touch your eye, eyelid, or any other surface.

The most common side effects of YUVEZZI are headache, impaired vision, and eye pain and/or eye irritation upon use. These are not all of the possible side effects of YUVEZZI.

Most side effects were generally mild, didn't last long, and went away on their own.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see the [Brief Summary](#) for more information.

About **[Insert Practice Name]**

[Insert 2-3 sentences about the practice]

To learn more, visit: **[Insert practice website]** and connect on **[Insert practice social media, as relevant]**.

Contact:

[Name]

[Phone and/or Email]

-
1. American Optometric Association Health Policy Institute. New Approaches to Presbyopia. 2023. Accessed November 5, 2025. Available at <https://www.aoa.org/AOA/Documents/Advocacy/HPI/presbyopia%20brief%20HPI%20Final.pdf>.
 2. National Eye Institute. Presbyopia. National Eye Institute. December 4, 2024 <https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/presbyopia>. Accessed March 30, 2026.
 3. Fricke TR, Tahhan N, Resnikoff S, et al. Global Prevalence of presbyopia and vision impairment from uncorrected presbyopia: systematic review, meta-analysis and modelling. *Ophthalmology*. 2018;125(10):1492–9.
 4. Glasser A, Campbell MCW. Biometric, optical and physical changes in the isolated human crystalline lens with age in relation to presbyopia. *Vision Research*. 1999;39:1991–2015. doi:10.1016/S0042-6989(98)00283-1. <https://www.sciencedirect.com/science/article/pii/S0042698998002831?via%3Dihub>.
 5. YUVEZZI US Prescribing Information.

